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ABSTRACT 
 
Aim: We aimed to investigate chemotherapy effect of resectable colorectal cancer with liver 
metastasis (CRLM) on the functions of intrahepatic immune cells. 
Methods: We classified patients into adjuvant chemotherapy (bevacizumab+CapeOX) after 
hepatectomy group (group A) and neoadjuvant chemotherapy followed by hepatectomy group 
(group B), and collected peripheral blood mononuclear cells (PBMCs) and liver mononuclear 
cells (LMNCs) to ascertain phenotypic and functional differences. 
Results: There were no significant differences in lymphocyte fractions of either PBMCs or 
LMNCs between groups, except for the significantly lower percentage of natural killer (NK) 
cells in LMNCs in group B than in group A. Significantly higher percentage of 
NKG2D-positive NK cells in PBMCs, and percentage of TRAIL-, NKp30-, and 
SIRPβ-positive NK cells in LMNCs were found in group B. Furthermore, significantly higher 
expression of NKG2D and SIRPβ in peripheral blood NK cells and of NKp46 and CD122 in 
liver NK cells were found in group B. When LMNCs were incubated with IL-2 in vitro, no 
difference was observed in the expression of these molecules in NK cells between groups. 
Consistently, there was no difference in the cytotoxic activity of those LMNCs against a 
colon adenocarcinoma cell line between groups. 
Conclusion: CRLM patients treated with neoadjuvant chemotherapy exhibited enhanced 
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expression of activation markers on peripheral blood and liver NK cells in comparison with 
patients who did not receive therapy; however, the difference in those function remains 
unclear. These results suggest that neoadjuvant chemotherapy does not have a negative 
impact on intrahepatic immune cells in resectable CRLM patients. 
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INTRODUCTION 
 
The primary clinical complication of colorectal cancer (CRC) is the invasion of tumor cells 
into distant organs and outgrowth of metastases. CRC with liver metastasis (CRLM) is a 
major prognostic factor for CRC patients (1, 2). The disease-specific mortality of progressive 
CRC has decreased significantly in past decades with novel chemotherapeutic agents, such as 
oxaliplatin and irinotecan, and molecular-targeted drugs, such as bevacizumab, a recombinant 
humanized monoclonal antibody that targets vascular endothelial growth factor (VEGF) (3). 
Adding bevacizumab to chemotherapy significantly reduces residual viable tumor cell 
volume in resected tumors and increases the proportion of patients eligible for liver 
metastasis resection, when compared with chemotherapy alone (4, 5).  
Despite recent advancements in chemotherapy strategies for the treatment of advanced CRC 
patients, surgical resection of CRLM has been established as the treatment of choice and is 
the most effective and potentially curative therapy (6-10). Furthermore, surgical resection for 
CRLM combined with systemic adjuvant chemotherapy has a potential benefit to be curative 
for CRLM patients (11, 12). Meanwhile, the advantage of neoadjuvant chemotherapy in 
initially resectable CRLM patients is the treatment of undetected distant micrometastasis, 
thereby reducing recurrence risk after surgery (13). Although various studies have reported on 
the treatment strategy in resectable CRLM patients, the optimal treatment sequence remains 
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unclear. 
Considering the impact of both surgical resection and chemotherapy on the host immunity is 
imperative in the treatment of resectable CRLM. Immune systems surrounding cancer cells 
are known to play crucial roles in regulating cancer cell proliferation, invasion, and 
metastasis through immunosurveillance (14, 15). Our group and other researchers have 
demonstrated that the decreased activity of immune cells in the liver after hepatectomy leads 
to tumor growth in mice (16, 17). While the influence of surgery on immune-surveillance 
against cancer cells has been occasionally investigated, the influence of chemotherapy on that 
remains to be elucidated. Studies have reported that the presence of tumor-infiltrating 
immune cells, such as natural killer (NK) cells and T cells, in CRLM patients improved the 
overall survival (OS) (6, 18). NK cells are part of the innate immune system and may provide 
a first line of defense against neoplastic cells by exerting an effector function without the 
necessity for priming (19). In addition, NK cells are abundant in human liver, and liver NK 
cells have remarkably higher cytotoxic activity against neoplastic cells than peripheral blood 
NK cells (20, 21). Such unique anatomical distribution and functional property of NK cells in 
the liver prompt us to investigate the influence of chemotherapy, particularly neoadjuvant 
chemotherapy, on the immunity of NK cells in the liver of CRLM patients. 
In clinical setting, we are conducting a phase II/III randomized clinical trial in Hiroshima 
Surgical Study Group of Clinical Oncology (HiSCO) to determine whether neoadjuvant 
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chemotherapy followed by hepatectomy is superior to adjuvant chemotherapy after 
hepatectomy in resectable CRLM patients regarding progression-free survival (PFS), OS, and 
time to treatment failure. Since this clinical trial provided a good opportunity to obtain 
samples from resectable CRLM patients, who were either previously exposed or not exposed 
to chemotherapy, we additionally but separately designed an independent study to investigate 
the effect of neoadjuvant chemotherapy in resectable CRLM patients on liver NK cell activity 
as subanalysis of a clinical trial.  
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MATERIALS AND METHODS 
 
Study Design and Procedures 
We have been conducting a phase II/III randomized clinical trial in HiSCO (Hiroshima, 
Japan) registered with national review board (HiSCO-01, University Hospital Medical 
Information [UMIN] 00000378) to elucidate whether the neoadjuvant chemotherapy, 
bevacizumab combined with XELOX (CapeOX: capecitabine plus oxaliplatin), followed by 
hepatectomy is superior to adjuvant chemotherapy after hepatectomy in resectable CRLM 
patients. From June 2010, a planned cohort of 260 macroscopically-resectable CRLM 
patients who fulfilled the inclusion criteria (Table 1) were randomly assigned to either an 
adjuvant chemotherapy (eight courses of bevacizumab 7.5 mg/kg with capecitabine 2000 
mg/m2 plus oxaliplatin 130 mg/m2) after hepatectomy group (group A) or neoadjuvant 
chemotherapy followed by hepatectomy group (group B) based on the discretion of the 
reference physician in the HiSCO group. In group A, adjuvant chemotherapy was 
administered within 8 weeks after hepatectomy. CapeOX therapy was initiated, of which 
eight courses (each lasting 3 weeks) were administered. Bevacizumab was administered in 
the second and subsequent courses. In group B, neoadjuvant chemotherapy comprised eight 
courses of bevacizumab plus CapeOX therapy and each course lasted for 3 weeks. 
Bevacizumab was withdrawn in the final course. Surgical resection was performed within 2 
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and 8 weeks after the completion of neoadjuvant chemotherapy. 
This study was additionally designed as subanalysis of a randomized clinical trial in 
HiSCO-01 to investigate the effect of chemotherapy on the functions of intrahepatic immune 
cells in resectable CRLM patients. From February 2011, we conducted this additional study 
in 30 consecutive patients. The number of samples was determined on the basis of our 
previous study, which demonstrated the relationship between clinical pathology and 
activation status of liver and peripheral blood NK cells (22, 23). We calculated sample size to 
detect the difference among percentage positive NK cells under the assumption that expected 
difference 20%, SD 15%, alpha level 5% and 80% power, and it was 10 for each group. 
Assuming a dropout rate of 33%, target sample size was set as 15 for each group. We 
obtained clinical data, including patients’ characteristics, and data obtained by analysis for 
comparative assessment. The research was conducted in compliance with the Declaration of 
Helsinki published by the World Medical Association and the Ethical Guidelines for Clinical 
Research published by Ministry of Health, Labor, and Welfare, Japan. In addition, this study 
was approved by the Institutional Review Board (IRB) of all institutions participating in this 
study. We obtained written informed consent from all patients before enrollment. 
 
Collection of Mononuclear Cells 
We analyzed the contents of immune cell and phenotype using peripheral blood 
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mononuclear cells (PBMCs) and liver mononuclear cells (LMNCs) obtained from eligible 
patients in both groups. We collected blood samples at the time of hepatectomy, and PBMCs 
were isolated by gradient centrifugation with Separate-L (Muto Pure Chemicals Co., Ltd, 
Tokyo, Japan) from 40 mL heparinized peripheral blood. In addition, LMNCs were obtained 
by ex vivo perfusion through the portal vein of resected livers from CRLM patients as 
previously described (20). Effluents were condensed by centrifugation, and LMNCs were 
isolated by gradient centrifugation with Separate-L. 
 
Flow Cytometric Analyses 
We performed flow cytometric (FCM) analyses using FACSCalibur cytometer (BD 
Biosciences, San Jose, CA) and FlowJo 7.6.5 software (TreeStar Inc., Ashland, OR). Based 
on a previous study (23), the monoclonal antibodies (mAbs) used for surface staining of 
lymphocytes to assess the phenotypic properties of NK cells were as follows: fluorescein 
isothiocyanate (FITC)-conjugated anti-CD3 (HIT3a), anti-CD56 (B159), anti-CD19 (HIB19); 
phycoerythrin (PE)-conjugated anti-NKp30 (p30-15), anti-NKp46 (9E2), anti-CD122 
(Mik-β3), and anti-CD56 (B159), anti-CD11b (ICRF44); and allophycocyanin 
(APC)-conjugated anti-CD3 (HIT3a), anti-natural-killer group 2, member D (NKG2D; 1D11), 
purchased from Becton Dickinson (San Jose, CA); PE-conjugated antitumor necrosis 
factor-related apoptosis-inducing ligand (TRAIL; RIK-2; eBioscience, Santa Clara, CA); and 
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PE-conjugated anti-signal regulatory protein β (SIRPβ; B4B; BioLegend, San Diego, CA). 
Mouse IgG1κ was used as an isotype-matched control. Dead cells were excluded from the 
analysis by light scatter analysis and propidium iodide staining. 
 
Cytotoxicity Assays 
LMNCs were suspended in DMEM medium (Gibco, Grand Island, NY) supplemented with 
10% heat-inactivated fetal calf serum (Sanko Chemical Co., Tokyo, Japan), 25 mM HEPES 
buffer (Gibco), 50 µM mercaptoethanol (Katayama Chemical Co., Osaka, Japan), 50 U/mL 
penicillin, and 50 µg/mL streptomycin (Gibco). In addition, LMNCs were used for 
phenotypic analyses and cultured with or without human recombinant interleukin (IL)-2 (100 
Japanese reference U/mL; Takeda, Tokyo, Japan) for 3 days at 37°C in 5% CO2. Cultured 
cells were harvested and used for phenotypic analyses and cytotoxicity assays, which were 
performed using FACSAriaII (BD Biosciences) and FlowJo 7.6.5 software. Furthermore, we 
used DLD-1 cells (Japanese Collection of Research Bioresources Cell Bank, Osaka, Japan), 
established from a colon adenocarcinoma cell line (Dukes type C), as target cells. The FCM 
assay was performed to evaluate cell-mediated cytotoxicity, as described previously (24) with 
minor modifications. DLD-1 cells were labeled with PKH using the PKH26 Fluorescent Cell 
Linker Kits (Sigma-Aldrich, St. Louis, MO) according to the manufacturer’s instructions. 
PKH-labeled target cells (1 × 105) and prepared effector cells were added to a total of 200 µL 
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in a round-bottom, 96-well microtiter plates (BD Falcon, San Diego, CA) in duplicate wells. 
After 4-h incubation, cells were harvested and stained with 4′,6-diamidino-2-phenylindole 
(DAPI; Vector Laboratories, Burlingame, CA). As a control, target cells were incubated in 
culture medium alone to determine spontaneous cell death. The number of PKH-labeled 
target cells that were killed was determined by analyzing PKH and DAPI double-positive 
cells using FCM. The cytotoxicity percentage was calculated using the following equation: 
% cytotoxicity = ［(% experimental PKH+ DAPI+ targets) – (% spontaneous PKH+ DAPI+ 
targets)］ / ［100 – ( % spontaneous PKH+ DAPI+ targets)］ × 100. 
 
Real-time Polymerase Chain Reaction 
Total RNA was isolated from resected tumor tissues of CRLM using RNeasy Mini kit 
(Qiagen, Limburg, the Netherlands) and reverse-transcribed using ReverTra Ace qPCR RT 
Kit (Toyobo Life Science, Tokyo, Japan) according to the manufacturer’s instructions. We 
determined the relative copy numbers of NKG2D ligands, such as MHC class I 
polypeptide-related sequence A (MICA), MHC class I polypeptide-related sequence B 
(MICB), and UL16-binding protein 2 (ULBP2), by real-time polymerase chain reaction 
(PCR) using NKG2D ligand-specific primer pairs and normalized to the expression of 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH). We amplified the resulting cDNA 
with Rotor-Gene 3000 and Rotor-Gene SYBR Green PCR Kits (Qiagen) and analyzed data 
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using ∆Ct method for relative quantification. We performed all RT-PCR experiments using 2 
µL cDNA with the following cycling parameters: 40 cycles at 95°C for 5 s and 60°C for 10 s. 
The following primers were used: MICA, 5 ′ -CCTTGGCCATGAACGTCAGG-3 ′ 
(forward) and 5 ′ -CCTCTGAGGCCTCGCTGCG-3 ′  (reverse); MICB, 5 ′
-ACCTTGGCTATGAACGTCACA-3 ′  (forward) and 5 ′
-CCCTCTGAGACCTCGCTGCA-3 ′  (reverse); ULBP2, 5 ′
-CAGAGCAACTGCGTGACATT-3 ′  (forward) and 5 ′
-CATGCCCATCAAGAAGTCCT-3′ (reverse); and GAPDH (used as an internal control), 
5 ′ -CAACGGATTTGGTCGTATTGG-3 ′  (forward) and 5 ′
-CCATGGGTGGAATCATATTGG-3′ (reverse). 
 
Image-Confirmed and Pathological Chemotherapy Response Rates 
We evaluated the image-confirmed chemotherapy response rate according to the response 
evaluation criteria in solid tumors (RECIST v1.1) (25) as follows: complete response (CR), 
partial response (PR), progressive disease (PD), and stable disease (SD). Furthermore, the 
pathological chemotherapy response rate was defined according to the criteria of the Japanese 
Society for Cancer of the Colon and Rectum (JSCCR) (10) as follows: grade 0, grade 1a, 
grade 1b, grade 2, and grade 3. In this study, the pathologist randomly selected CRLM slides 
stained with hematoxylin-eosin, and evaluated chemotherapy effectiveness without 
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knowledge about clinical history of the patients. 
 
Statistical Analysis 
Data are presented as the mean ± standard deviation (SD). We performed statistical analyses 
using JMP 11 for Windows (SAS Institute, Inc., Cary, NC). Statistical significance of the 
differences observed between groups was evaluated by Mann-Whitney U-test and ANOVA 
analysis with Scheffe F test. P < 0.05 was considered statistically significant.  
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RESULTS 
 
Patient Demographics and Clinicopathological Characteristics 
In this prospective open-label study, we enrolled CRLM patients previously untreated with 
chemotherapy. In group B, 11 of 15 patients were evaluable for preoperatively administered 
bevacizumab combined with CapeOX at the time of sampling. In group A, 15 patients were 
used as controls without the influence of chemotherapy. The differences in the number of 
cases between these both groups were the exclusion of some cases because of complications 
of chemotherapy, treatment refusal, and another carcinoma occurrence. Table 2 summarizes 
patients’ characteristics in this study. No significant differences existed in patients’ 
characteristics, including sex, age, synchronous/metachronous, location of primary tumor, 
clinical stage, tumor differentiation, surgical procedure for hepatectomy, mean resected liver 
weight, and count of intrahepatic immune cells collected by perfusion between these groups. 
Synchronous liver resection with primary resection was performed in one patient in Group A 
(1/10) and another patient in Group B (1/5) with synchronous metastasis. These patients 
showed no characteristic findings. 
 
Neoadjuvant Chemotherapy did not Affect Cell Numbers or the Proportion of Lymphocytes in 
PBMCs and LMNCs, Except for the Proportion of Liver NK Cells 
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A comparison of the numbers of PBMCs, lymphocytes, and monocytes revealed no 
significant differences between groups A and B (Fig. 1a, c, e), and no significant differences 
were observed between the two groups in terms of the numbers of LMNCs, lymphocytes, and 
monocytes collected during liver perfusion from resected livers (Fig. 1b, d, f). We compared 
proportion of NK cells, NKT cells, T cells, and B cells in both PBMCs and LMNCs between 
both groups to analyze the effect of neoadjuvant chemotherapy on lymphocyte populations. 
No significant differences were found in the proportion of NK cells in PBMCs (Fig. 1g). 
However, the proportion of NK cells in LMNCs was significantly lower in group B than in 
group A (17.1 ± 10.0 versus 28.2% ± 12.2%; P = 0.03; Fig. 1h). The proportion of NKT cells, 
T cells, and B cells in both PBMCs and LMNCs did not differ significantly between two 
groups (Fig. 1i-n). Further, we evaluated the correlation of NK and T cells to examine the 
relationship between innate and adaptive immunities. In both groups, a positive correlation 
was noted between the number of peripheral blood NK cells and that of T cells. Moreover, 
although there was a positive correlation between the number of liver NK cells and that of T 
cells in group B, this was not observed in group A (Supplemental Figure S1). 
 
Potential Augmentation of the NK Cell Activity in the Liver of Patients Receiving 
Neoadjuvant Chemotherapy Followed by Hepatectomy 
We assessed the phenotypic differences in NK cells, which play a pivotal role in tumor 
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surveillance, to investigate the effect of neoadjuvant chemotherapy on the innate-immune 
system in CRLM patients. The mean fluorescent intensity (MFI) of NKG2D and SIRPβ, 
which are associated with the small transmembrane adapter protein DAP12; transduce 
stimulatory signals (26); and are expressed on activated NK cells (27) on peripheral blood 
NK cells, was significantly higher in group B than in group A (P = 0.03 and P = 0.04, 
respectively; Fig. 2a). The proportion of NKG2D-positive NK cells was also significantly 
elevated in PBMCs from group B compared with group A (P = 0.04; Fig. 2b). The proportion 
of TRAIL-positive NK cells significantly increased in LMNCs from group B compared with 
that from group A (P = 0.03; Fig. 2d). Reportedly, TRAIL can induce either apoptosis by 
Fas-associated death domain-dependent mechanism or necrosis through receptor-interactive 
peptide-dependent cascade through the ligation of its death domain-containing receptors 
under physiological conditions (28). MFI of NKp46 and CD122, known as IL-2Rβ, on liver 
NK cells was significantly higher in Group B than in group A (P = 0.04 and P = 0.03, 
respectively; Fig. 2c). Proportion of NKp30 and SIRPβ-positive NK cells significantly 
increased in LMNCs from group B compared with LMNCs from group A (P = 0.04 and P = 
0.02, respectively; Fig. 2d). Overall, the expression of cytotoxic and activation molecules in 
peripheral blood and liver NK cells tended to be enhanced in group B compared with group A. 
Further, we confirmed whether the adverse events of neoadjuvant chemotherapy is involved 
in the functions of NK cells. Notably, in group B, there was no difference in terms of the 
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expression of surface molecules on NK cells between cases with myelosuppression (n = 4) 
and those without myelosuppression (n = 7) (Supplemental Figure S2). 
Then, we investigated the influence of the cytotoxic activity of LMNCs against DLD-1 CRC 
cells. We stimulated LMNCs obtained from each group with IL-2 and evaluated phenotypic 
alterations in these cells using the FCM assay. Of note, IL-2-stimulated LMNCs were used as 
effector cells rather than freshly isolated LMNCs because of limited level of cytotoxic 
activity of freshly isolated LMNCs (data not shown). The IL-2 stimulation increased the 
expression of activated molecules such as TRAIL, NKp30, NKp46, and NKG2D, on liver 
NK cells compared to the naive condition in both groups, and the remarkable difference in 
the expression levels of surface molecule in IL-2-stimulated LMNCs from both groups was 
no longer observed (Fig. 3a, b). Consequently, the cytotoxic activity of IL-2-stimulated 
LMNCs obtained from both groups showed no significant differences (Fig. 3c).  
 
Neoadjuvant Chemotherapy did not Affect the Expression Levels of NKG2D Ligands in Liver 
Tumors. 
We then evaluated the influence of chemotherapy on the expression of tumor-specific 
antigens that were theoretically recognized by NK cells on tumors from CRLM patients. The 
ligands for NKG2D comprised human class I-like molecules MICA, MICB, and ULBPs, 
which are stress-induced molecules expressed by tumors of epithelial origin and activate the 
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NK cell cytotoxicity through their NKG2D receptor (29, 30). Although we performed 
immunohistochemistry using frozen sections as a preliminary experiment, the evaluation of 
the expression of MICA, MICB, and ULBP2 in tumor tissue was challenging. Hence, we 
examined the expression levels of these molecules in liver specimens from patients in each 
group by RT-PCR. Ligands for NKG2D were evaluable in 13 of 15 samples in group A and 5 
of 11 samples in group B. However, we could not perform complete sequencing on other 
samples because of a lack of DNA or degradation of DNA. The difficulty in extracting DNA 
from liver tissue because of tumor necrosis accounted for small number of samples in group 
B. Furthermore, although we could not exclude the possibility of inconsistencies arising from 
this limitation, no significant differences were observed in expression levels of these three 
targets between two groups (Fig. 4).  
 
No Association between NK Cell Activation Marker Expression and Clinically Evaluated 
Chemotherapy Response Rate  
To investigate the effect of neoadjuvant chemotherapy on tumor shrinkage, we assessed the 
correlation between NK cell surface activation markers, such as TRAIL, NKp30, NKp46, 
NKG2D, CD122, and SIRPβ, in PBMCs and LMNCs and the chemotherapy response 
clinically evaluated using RECIST or the histological treatment response (grade 
classification) were studied in patients receiving neoadjuvant chemotherapy followed by 
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hepatectomy. The evaluation of RECIST in 11 patients revealed no CR cases, whereas there 
were 6 PR cases (54.6%), 4 SD cases (36.4%), and 1 PD case (9.0%). Four cases were 
classified as grade 1a (36.4%), 2 cases as grade 1b (18.2%), 0 case as grade 2a (0%), 4 cases 
as grade 2b (36.4%) and 1 case as grade 3 (9.0%). Despite confirming the treatment effect in 
various cases, we observed no significant correlation between the expression levels of each 
activated molecule in NK cells and image-confirmed or pathological chemotherapy response 
rates (Fig. 5).  
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DISCUSSION 
 
The effect of chemotherapeutic agents on the immune cell function is considered to be 
involved in the immunosuppression associated with myelosuppression or drug cytotoxicity 
(31). However, the immune cell function, particularly regarding liver immunity at the local 
anatomical site with distant CRC metastasis, during chemotherapy, remains unclear. To 
resolve this clinical question, we separately designed a subanalysis study of a phase II/III 
randomized clinical trial, which was conducted by the HiSCO group, to investigate whether 
chemotherapeutic or surgical precedence as a primary treatment has a clinical advantage for 
treatment of resectable CRLM patients.  
To date, several studies have reported correlations between immunosuppressed status and 
tumor recurrence or patient prognosis in various malignant tumors. Reportedly, preoperative 
variables, including decreased lymphocyte count, increased monocyte count, and elevated 
neutrophil-to-lymphocyte ratio, are associated with poor prognosis in cancer patients (32, 33). 
In addition, perioperative changes in peripheral blood monocyte counts are independent risk 
factors for OS after hepatectomy and may reflect an immunosuppressive state (34). In this 
study, PBMC and LMNC counts, including those of lymphocytes and monocytes, of the 
group receiving neoadjuvant chemotherapy were not less than those of the group primarily 
receiving hepatectomy. Hence, preoperative introduction of bevacizumab combined with 
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CapeOX chemotherapy for the treatment of CRLM may not weaken the immune system 
function in these patients. Generally, the innate and adaptive immune systems can protect the 
host against tumor development via immunosurveillance. In this study, we showed a positive 
correlation between the number of liver NK cells and that of T cells in the group receiving 
neoadjuvant chemotherapy followed by hepatectomy, possibly indicating the effect of the 
innate immune system against the adaptive immune system. However, further investigation is 
warranted to describe the precise role of neoadjuvant chemotherapy in adaptive immunity 
following NK cell activation in patients with resectable CRLM. 
Several investigators have reported that patients with a relatively dense infiltration of 
malignant tumors by NK cells exhibited better clinical outcomes (18, 35, 36). The outcomes 
of NK cell-target cell interactions are regulated by fine integrative balance between inhibitory 
and activating receptors expressed on NK cells and their ligands on target cells (37). In 
addition, several studies have demonstrated that a majority of CRCs exhibit diminished MHC 
class I expression, making them particularly vulnerable to NK cell-mediated killing and these 
patients show survival benefit (38, 39). However, the precise mechanism of NK cell function 
in CRLM tissues remains unclear. In this study, proportion of peripheral blood NK cells did 
not significantly differ between two groups, although the proportion of liver NK cells was 
significantly lower in neoadjuvant chemotherapy group. We collected NK cells in the liver by 
nondestructive perfusion method to avoid possibility of enzyme-induced alteration or 
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disruption of specific epitopes and evaluate the effect of chemotherapy on NK cells in the 
liver. In this case, the tumor infiltrated mononuclear cells, among which NK cell fraction 
might be enriched through potential chemotaxis from the tumor endothelium, are likely to be 
present in the perfusate, hence the collected LMNCs contain tumor infiltrated immunocytes. 
Because >50% of the patients displayed PR in the neoadjuvant chemotherapy group, the 
number of liver NK cells that infiltrated into the tumor decreased due to tumor shrinkage. 
Consequently, the proportion of NK cells among LMNCs possibly reduced in these patients. 
Another possibility might be that the chemotherapy comprising bevacizumab plus CapeOX 
directly influences the existence of NK cells in the liver. To address this issue, further 
investigation may be required. 
The efficacy of NK cell-mediated tumor clearance depends on the type of NK cells that are 
present in the tissue, or that have migrated to the tumor site from peripheral blood (40). The 
non-classical MHC class I antigens, such as MICA, MICB, and ULBPs, can engage a 
stimulatory receptor on NK cells comprising a heterodimeric complex of NKG2D/DAP10, a 
cell-surface adaptor molecule involved in signal transduction (29, 41). The activation signal 
resulting from the engagement of NKG2D-DAP10 overrides the inhibitory signal from MHC 
class I molecules leading to target cell lysis (30, 42). Reportedly, high density of intratumoral 
NKp46-expressing NK cells was associated with OS in CRLM patients who received 
neoadjuvant chemotherapy (18). In this study, the expression of activation markers/effector 
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molecules on both peripheral and liver NK cells of patients treated with neoadjuvant 
chemotherapy was enhanced than that in patients who did not receive chemotherapy; 
however, the proportion of NK cells among LMNCs was reduced. Our results indicated the 
increased NKG2D-expressing peripheral blood NK cells and NKp46-expressing liver NK 
cells in the neoadjuvant chemotherapy group. Furthermore, the proportion of TRAIL-positive 
NK cells in LMNCs significantly increased in the neoadjuvant chemotherapy group. Studies 
have shown TRAIL to be critical among the TNF family members in the NK cell-mediated 
antitumor function (20, 43). Besides, CRC cells are susceptible to TRAIL-induced apoptosis, 
both as a single agent of recombinant TRAIL and combined with chemotherapy and targeted 
therapies (44). Thus, administration of preoperative chemotherapeutic agents phenotypically 
activated liver NK cells; however, underlying mechanism remains unclear. This seems 
consistent with a previous finding that dying tumor cells treated with chemotherapeutic 
agents release proinflammatory cytokines that are crucial in the stimulation of protective 
anti-cancer immune responses (45). Thus, it is possible that neoadjuvant chemotherapy 
enhances NK cell-mediated cytotoxicity against tumor cells; however, we could not 
demonstrate the enhancement of cytotoxic activity in our experimental system. Its clinical 
significance remains completely unknown. Furthermore, we confirmed the effect of 
neoadjuvant chemotherapy on NK cells and showed that myelosuppression did not affect at 
least the expression of the surface molecules on NK cells in cases wherein chemotherapy 
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could be continued in the group receiving neoadjuvant chemotherapy followed by 
hepatectomy. However, the effects of the adverse events of neoadjuvant chemotherapy on 
intrahepatic immune cells are still unknown. 
In addition, the NKG2D ligand expression is reportedly correlated with better clinical 
prognosis in CRC (46). In this study, neoadjuvant chemotherapy did not affect the expression 
of non-classical MHC class I antigens on CRLM tumor tissues, suggesting that 
chemotherapeutic agents might not diminish susceptibility to NK cell-mediated anti-tumor 
cytotoxicity. Cytotoxic activity of IL-2-stimulated LMNCs from neoadjuvant chemotherapy 
group was not significantly different from that of the group that received surgery first. These 
results suggest that chemotherapy does not have a negative impact on intrahepatic immune 
cells in resectable CRLM patients. 
Recently, a complete pathological response was shown to be correlated with high rates of 
the OS and PFS in advanced CRC patients who had undergone neoadjuvant and conversion 
chemotherapy before resection of CRLM (47). In the present study focusing on the early 
limited phase until hepatectomy, we found no significant correlation between the expression 
strength of activating markers on NK cells and the image-confirmed and pathological 
chemotherapy response rates at the time of surgical treatment. The main HiSCO-01 trial is 
still under long-term follow-up observations, thereby not allowing us to evaluate the 
correlation between the expression strength of the activating markers on NK cells and 
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survival benefits.  
In summary, this study suggests that neoadjuvant chemotherapy for the treatment of 
resectable CRLM induces the activation of peripheral blood and liver NK cells; however, its 
clinical significance remains unknown.  
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FIGURE LEGENDS 
 
Figure 1. Effects of neoadjuvant chemotherapy on lymphocyte subsets in both peripheral 
blood mononuclear cells (PBMCs) and liver mononuclear cells (LMNCs).  
The numbers and proportions of PBMCs and LMNCs were analyzed by the FCM assay in 
groups A and B (n = 15 and 11, respectively). a, A comparison of the number of PBMCs per 
mL of blood between the two groups; b, a comparison of the number of LMNCs collected by 
liver perfusion per g of resected liver between the two groups; c-f, a comparison of the 
number of lymphocytes and monocytes in PBMCs and LMNCs between the two groups.; g-n, 
a comparison of the percentages of NK cells, NKT cells, T cells, and B cells in PBMCs and 
LMNCs between the two groups. *P < 0.05. 
 
Figure 2. Neoadjuvant chemotherapy increased the expression of activation markers in 
peripheral blood and liver NK cells.  
The FCM analysis of PBMCs and freshly isolated LMNCs obtained from liver perfusate 
after staining with CD3 and CD56 mAbs together with additional mAbs was performed (n = 
15 [group (Gr) A]; n = 11 [Gr B]). a, Histograms represent the log fluorescence intensities 
obtained by staining for TRAIL, NKp30, NKP46, NKG2D, CD122, and SIRPβ after gating 
of CD3–CD56+ peripheral blood NK cell subsets obtained from patients. Dotted lines, 
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negative control staining with isotype-matched mAbs; numbers above each histogram, mean 
± SD of the MFI of targeted molecule expression on peripheral blood NK cells. b, Each point 
indicates the percentage of peripheral blood NK cells in each group that was positive for the 
TRAIL, NKp30, NKP46, NKG2D, CD122, and SIRPβ expression. c, Histograms 
representing the log fluorescence intensities obtained by staining for TRAIL, NKp30, NKP46, 
NKG2D, CD122, and SIRPβ after gating of CD3–CD56+ liver NK cell subsets obtained from 
patients. Dotted lines, negative control staining with isotype-matched mAbs; numbers above 
each histogram, mean ± SD of the MFI of targeted molecule expression on liver NK cells. d, 
Each point indicates the percentage of liver NK cells in each group that was positive for the 
TRAIL, NKp30, NKP46, NKG2D, CD122, and SIRPβ expression. *P < 0.05. 
 
Figure 3. Neoadjuvant chemotherapy did not suppress the cytotoxic activity of 
cytokine-stimulated LMNCs.  
The FCM analyses of LMNCs cultivated with recombinant IL-2 for 3 days were performed 
after staining with mAbs against CD3 and CD56 (n = 11 [Gr A]; n = 5 [Gr B]). a, Histograms 
represent the log fluorescence intensity obtained by staining for TRAIL, NKp30, NKP46, 
NKG2D, CD122, and SIRPβ after gating of CD3–CD56+ IL-2-stimulated liver NK cell 
subsets obtained from patients. Dotted lines, negative control staining with isotype-matched 
mAbs; numbers above each histogram, mean ± SD of the MFI of targeted molecule 
Page 40 of 48Annals of Gastroenterological Surgery
For Review Only
40 
 
expression on IL-2-stimulated liver NK cells. b, Each point indicates the percentage of 
IL-2-stimulated liver NK cells in each group that was positive for the TRAIL, NKp30, 
NKP46, NKG2D, CD122, and SIRPβ expression. c, the NK cytotoxic activity of 
IL-2-stimulated LMNCs against DLD-1 target cells was compared between group A (dotted 
line) and group B (solid line) and analyzed using an FCM-based cytotoxic assay. All data are 
expressed as mean ± SD (n = 4 [Gr A]; n = 4 [Gr B]).  
 
Figure 4. Neoadjuvant chemotherapy did not affect the expression levels of MICA, MICB, 
and ULBP2 in liver tumors. 
The expression levels of NKG2D ligands (MICA, MICB, and ULBP2) in resected liver 
specimens of CRLM from each group were investigated (n = 13 [Gr A]; n = 5 [Gr B]). RNA 
from liver tumors was extracted and reverse-transcribed. Relative copy numbers of NKG2D 
ligands were determined by real-time PCR using each NKG2D ligand-specific primer pair 
and normalized to the expression of GAPDH. 
 
Figure 5. Neoadjuvant chemotherapy did not correlate with the clinical/pathological response 
rates and the expression levels of surface molecules on NK cells. 
Clinical evaluation of response by the RECIST and histological evaluation of treatment 
response (grade classification) were performed in group B (n = 11). a, the relationships 
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between TRAIL, NKG2D, and SIRPβ on peripheral blood NK cells and clinical response 
determined by the RECIST or histological treatment response (grade classification) were 
studied. b, The relationships between TRAIL, NKp30, NKp46, CD122, and SIRPβ on liver 
NK cells and clinical determined by the RECIST or histological treatment response (grade 
classification) were studied.  
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Table 1. Eligibility Criteria 
 
Eligibility Criteria
 
(1)
 
a primary lesion histologically diagnosed as CRC
 
(2)
 
the presence of CRLM of stage H1 or H2
 
(3)
 
the metastatic lesion in the liver required less than 60 % of liver resection
 
 
and allowed resection with a microscopically negative margin
 
(4)
 
no distant/peritoneal metastasis other than CRLM
 
(5)
 
the primary lesion had already been or could be resected with a microscopically negative margin
 
(6)
 
no history of local therapy such as radiofrequency ablation or chemotherapy/radiotherapy for the CRLM
 
(7)
 
no history of chemotherapy involving the use of oxaliplatin
 
(8)
 
the liver disease could be classified as Child-Pugh class A
 
(9)
 
no evident hemorrhage or obstruction arising from CRC
 
(10)
 
the patients were aged between 20 and 80 years during enrollment
 
(11)
 
the patient’s PS was either 0 or 1
 
CRC: colorectal cancer
 
CRLM: colorectal cancer with liver metastasis
 
 PS:performance status
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Table 2. Patients’ characteristics 
 
  Patients’ characteristics
 
 
 
 
 
Group A
 
Group B
 
P value
 
Eligible patients / enrolled patients
 
 
15 /15
 
11 / 15
 
 
Sex
 
Male
 
11
 
9
 
 
Female
 
4
 
2
 
1.00 
 
Age
 
Median (range)
 
66 (27 - 77)
 
66 (45 - 78)
 
0.78 
 
Relations of CRC  
and CRLM
 
Synchronous
 
10
 
5
 
 
Metachronous
 
5
 
6
 
0.43 
 
Location of Primary tumor
 
Colon
 
9
 
6
 
 
 
Rectum
 
5
 
4
 
 
 
Colon and Rectum
 
1
 
1
 
0.82
 
Clinical Stage
 
I
 
0
 
1
 
 
II
 
3
 
3
 
 
III
 
2
 
2
 
 
IV
 
10
 
5
 
0.55
 
Tumor Differentiation
 
Well
 
2
 
2
 
 
Moderately
 
12
 
9
 
 
Poorly
 
0
 
0
 
 
Mucinous
 
1
 
0
 
0.66
 
Hepatectomy
 
Partial resection
 
5
 
7
 
 
Segmentectomy
 
8
 
2
 
 
Lobectomy
 
2
 
2
 
0.18
 
Resection liver weight(g)
 
Median (range)
 
183 (26 - 845)
 
200 (10 - 638) 
 
0.80 
 
The number of LMNCs (×106)
 
Median (range)
 
127 (5 - 945)
 
42 (3 - 634)
 
0.34 
 
 
 
 
 
CRC：colorectal cancer, CRLM：colorectal cancer with liver metastasis, LMNCs: liver mononuclear cells 
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